The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance

The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance

Bibliographic Details
Main Authors: Toner, A P, McLaughlin, F, Giles, F J, Sullivan, F J, O'Connell, E, Carleton, L A, Breen, L, Dunne, G, Gorman, A M, Lewis, J D, Glynn, S A
Format: Online
Language:English
Published: Nature Publishing Group 2013
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3798953/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3798953/

Similar Items